Perfil
Yves Gonnissen is the founder of SEPS Pharma NV, which was founded in 2007.
He holds the title of Chief Executive Officer, Director & MD at SEPS Pharma NV since 2011.
Dr. Gonnissen is currently the Chairman at Amatsigroup SAS and the Managing Director & Director at Eurofins Amatsigroup NV.
Dr. Gonnissen previously worked as a Product Developer at Johnson & Johnson and as a Principal at Schering-Plough Corp.
He holds a doctorate degree from Ghent University and a graduate degree from Université Catholique de Louvain, which was conferred in 2002.
Cargos activos de Yves Gonnissen
| Empresas | Cargo | Inicio |
|---|---|---|
SEPS Pharma NV
 SEPS Pharma NV Pharmaceuticals: GenericHealth Technology SEPS Pharma NV provides controlled drug delivery and develops self emulsifying pro drug systems. Its services include preformulation, formulation development and analytical development. The company was founded on October 19, 2007 and is headquartered in Diepenbeek, Belgium. | Fundador | 19/10/2007 |
Amatsigroup SAS
 Amatsigroup SAS BiotechnologyHealth Technology Amatsigroup SASU provides human and veterinary drug development services. It offers bio services, pharmaceutical analysis solutions, formulation development, and manufacturing and clinical trial supply packaging and logistics. The company was founded on October 12, 2010 and is headquartered in Fontenilles, France. | Presidente | 29/06/2018 |
Eurofins Amatsigroup NV
 Eurofins Amatsigroup NV BiotechnologyHealth Technology Part of Eurofins Scientific SE, Eurofins Amatsigroup NV engages in the development of biological drugs. The company is based in Ghent, Belgium. The Belgian company was founded in 2007. The CEO is Yves Gonnissen. | Director Ejecutivo | 30/06/2017 |
Antiguos cargos conocidos de Yves Gonnissen.
| Empresas | Cargo | Fin |
|---|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Corporate Officer/Principal | - |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Formación de Yves Gonnissen.
| Ghent University | Doctorate Degree |
| Université Catholique de Louvain | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| Empresas privadas | 4 |
|---|---|
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
SEPS Pharma NV
SEPS Pharma NV Pharmaceuticals: GenericHealth Technology SEPS Pharma NV provides controlled drug delivery and develops self emulsifying pro drug systems. Its services include preformulation, formulation development and analytical development. The company was founded on October 19, 2007 and is headquartered in Diepenbeek, Belgium. | Health Technology |
Amatsigroup SAS
Amatsigroup SAS BiotechnologyHealth Technology Amatsigroup SASU provides human and veterinary drug development services. It offers bio services, pharmaceutical analysis solutions, formulation development, and manufacturing and clinical trial supply packaging and logistics. The company was founded on October 12, 2010 and is headquartered in Fontenilles, France. | Health Technology |
Eurofins Amatsigroup NV
Eurofins Amatsigroup NV BiotechnologyHealth Technology Part of Eurofins Scientific SE, Eurofins Amatsigroup NV engages in the development of biological drugs. The company is based in Ghent, Belgium. The Belgian company was founded in 2007. The CEO is Yves Gonnissen. | Health Technology |
- Bolsa de valores
- Insiders
- Yves Gonnissen
